Secondary CNS myeloma with remission after systemic CNS-penetrating agents

Neurooncol Adv. 2022 Jul 1;4(1):vdac106. doi: 10.1093/noajnl/vdac106. eCollection 2022 Jan-Dec.

Abstract

Background: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described.

Methods: We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment.

Results: The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone.

Conclusions: This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules.

Keywords: CNS myeloma; craniospinal irradiation; leptomeningeal; multiple myeloma.